Waldenstrom's Macroglobulinemia (WM) Treatment Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 – 2027)

Market Overview

Waldenstrom's Macroglobulinemia (WM) treatment market is anticipated to expand at a CAGR of 5.2% during the forecast period (2022-2027).

The worldwide health crisis of COVID-19 has affected the healthcare industry including its operations, commercial sales, regulatory interactions and inspections, and clinical trial recruitment and participation. COVID-19 has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions, social distancing, and business shutdowns. Additionally, the commercial or clinical supply of the medicines and drug candidates has also been impacted due to the shutdown of the company’s, or our third-party manufacturing facilities, distribution channels, and transportation systems, or shortages of raw materials and drug products which has reduced the company's revenue. For instance, AbbVie reported a 12.4% decrease in the net revenue generated by Imbruvica, used for waldenstrom's macroglobulinemia, in 2020 as compared to 2019.

The increasing prevalence and incidence of cases of waldenstrom's macroglobulinemia and increasing drug approvals by the regulatory bodies are escalating the growth of the market. The growth of the market is attributed to the increasing development of targeted and combination therapies across the globe. Furthermore, the rising geriatric population is expected to propel market growth. For instance, according to the statistics published by MedlinePlus genetics, it was observed that around 1,000 – 1,500 people are diagnosed with waldenstrom's macroglobulinemia (WM) each year in the United States, and is highest among individuals aged 60–79 years with an incidence rate of 3.4 per million among men and 1.7 per million among women in the United States. In addition, waldenstrom is predominantly affecting Caucasians.

Growing awareness about waldenstrom macroglobulinemia in low and middle-income countries, development of new diagnostic methods, rise in the need for novel therapies, and a constant number of clinical trials and heavy investments by the pharmaceutical companies and the government, can create remunerative opportunities and are speculated to bolster the market growth in the foreseeable future. For instance, in Nov 2020 AstraZeneca initiated a Phase II trial of bendamustine, rituximab, and the second-generation BTK Inhibitor Acalabrutinib in previously untreated waldenstrom's macroglobulinemia patients which is expected to complete by 2030. Bristol-Myers Squibb developing a Dasatinib drug in patients with waldenstrom macroglobulinemia (WM) progressing on Ibrutinib is under Phase 1 trial and is expected to be complete by 2024. BeiGene’s Brukinsa, Abbvie’s Imbruvica, and Gilead’s ibrutinib are the approved drugs that are being prescribed to the patients. Takeda has the highest number of completed clinical trials for waldenstrom's macroglobulinemia.

However, the Inadequate accessibility of disease-specific treatment and unmet needs including lack of curative therapies, high treatment cost, dearth of skilled workers, and strict safety guidelines are projected to impede the growth of the market.

Scope of the Report

As per the scope of the report, waldenstrom macroglobulinemia, also known as lymphoplasmacytic lymphoma, is an indolent subtype of non-Hodgkin lymphoma that originates in the bone marrow and starts producing abnormal white blood cells which hinder the normal functioning of the body and causes major complications. The major factor responsible for developing this disorder is the release of a hormone called interleukin (IL-6) from dendritic cells which aids in the growth of plasmacytoid lymphocytes.

It is suspected that the treatment options are bound to improve shortly, albeit at the cost of making its management increasingly complex. The Global Waldenstrom's Macroglobulinemia (WM) Treatment Market is segmented by treatment type (plasmapheresis, targeted therapy, chemotherapy, and Others) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Targeted Therapy Segment Expects to Register a High CAGR in the Forecast Period

The targeted therapy segment is expected to hold the largest share in this market segment. It is considered an is emerging pharmacotherapy for cancer. It is aimed at the disease blocking the growth and spread of cancer cells while minimizing the off-target side effects to the healthy/ normal cells. This leads to its higher adoption among other drugs, leading to its dominance in the market. Targeted therapy for waldenstrom macroglobulinemia includes monoclonal antibodies. For instance, anti-CD20 antibodies include obinutuzumab (Gazyva), ofatumumab (Arzerra), and rituximab-abbs (Truxima), Ibrutinib, Bortezomib (Velcade) are mostly used targeted therapy drugs for waldenstrom macroglobulinemia. According to the data published by National Cancer Institute, it has been observed that the targeted therapy agents, such as Imbruvica, Velcade, and Kyprolis, have shown improved treatment outcomes.

Furthermore, rising the number of pipeline candidates and an increased number of drug approvals are anticipated to propel the growth of this segment in the forecast period. For instance, according to ClinicalTrial.gov, 318 clinical studies are conducted by Institutes in collaboration with companies, 285 completed clinical studies, and 96 studies are either terminated, suspended, or withdrawn. In addition, Curis, X4, InnoCare, Ascentage, and Cellectar have 1 clinical trial in waldenstrom's macroglobulinemia disease.

Moreover, targeted therapy is being evaluated in COVID-19 treatment. Thus, encouraging clinicians to pursue targeted therapy agents during the pandemic is likely to create opportunities during the forecast period.

To understand key trends, Download Sample Report